UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/670,701	09/24/2003	Xing Su	070702006700	8780

7590 10/24/2006

Raj S. Dave
Morrison & Foerster LLP
1650 Tysons Blvd., Suite 300
McLean, VA 22102

EXAMINER	
FREDMAN, JEFFREY NORMAN	
ART UNIT	**PAPER NUMBER**
1637	

DATE MAILED: 10/24/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/670,701	SU ET AL.	
	Examiner	Art Unit	
	Jeffrey Fredman	1637	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *06 September 2006*.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-5,7 and 9-34* is/are pending in the application.

4a) Of the above claim(s) *4 and 27-34* is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1-3,5,7 and 9-26* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____.

DETAILED ACTION

Claim Interpretation

1. The claims as written clearly indicate that the "tag" can be anything from a nucleic acid or nucleotide to a fluorescent dye.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
>
> (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

3. Claims 1-3, 5, 7, 9, 11-16 and 21-26 are rejected under 35 U.S.C. 102(b) as being anticipated by Cleve et al (Mol. Cell. Probes (1998) 12:243-147).

Cleve teaches a method of claims 1 and 12 comprising:

(a) obtaining a barcode comprising two or more tags attached to an organic molecule backbone (see page 245, columns 1 and 2, where the branched DNA amplifier molecule has 15 branches with four copies of a sequence which bind to labelled probes, where binding of the labelled probes will result in two or more tags attached in a noncovalent manner to an organic molecule backbone),

(b) binding the barcode to a target (see page 245, column 2, where the probes are hybridized to a target),

(c) detecting the barcode bound to the target (see page 246, subheading "Flow Cytometry", where the barcodes are individually detected).

Wherein the backbone comprises one or more branched nucleic acids (see page 245, column 1 and 2, where branched nucleic acids with 15 branches are used) and

The barcode is detected by a technique of fluorescence spectroscopy (see figure 1, and page 246, column 1, where fluorescence spectroscopy is used to measure the beads).

With regard to claims 2-3, Cleve teaches single stranded nucleic acid probes (see page 245, columns 1 and 2, where the probes are single stranded).

With regard to claim 5, Cleve teaches the use of a fluorescent dye such as fluorescein (see page 246, column 2, where fluorescein is, of course, a fluorescent dyes, but also will function as a Raman tag).

With regard to claim 7, Cleve teaches branched nucleic acids where the branches are a predetermined locations on the backbone (see page 245, columns 1 and 2).

With regard to claim 9, Cleve teaches that the barcode binds via the oligonucleotide probe (see page 245, column 2).

With regard to claims 11, 13, 14, 25, 26, Cleve teaches a nucleic acid target and detection of the binding to the target (see page 245, column 2).

With regard to claim 15, 21, 24, Cleve teaches that four monomeric copies of the labelled probe will be noncovalently linked to the branched DNA to form a polymeric labeled branched DNA (see page 245, columns 1 and 2)

With regard to claim 16, Cleve teaches monomeric units with fluorescein, which is a Raman tag (see page 246, column 2)

With regard to claims 22-23, Cleve teaches binding of the branched DNA to a bead by a capture probe (see page 245, column 2).

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

5. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

6. Claims 1-3, 5, 7, 9-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Singer et al (U.S. Patent 6,534,266) in view of Urdea et al (U.S. Patent 5,635,352) and further in view of Horn et al (U.S. 2001/0009760).

Singer teaches a method of claims 1 and 12 comprising:

(a) obtaining a barcode comprising two or more tags attached to an organic molecule backbone (see column 8, lines 6-38, where oligonucleotides have five different fluorophores attached to the nucleic acid probe backbone to form a barcode),

(b) binding the barcode to a target (see column 8, lines 39-43, where the probes are hybridized to a target),

(c) detecting the barcode bound to the target (see column 8, lines 44-57, where the barcodes are individually detected).

Wherein the barcodes are detected by fluorescence spectroscopy (see column 9, lines 5-20).

With regard to claims 2-3, Singer teaches single stranded nucleic acid probes (see column 8, lines 16-38, where the oligonucleotides were synthesized, which necessarily is single stranded).

With regard to claim 5, Singer teaches the use of a variety of fluorescent dyes such as Cy3, Cy5, etc (see column 3, lines 1-2, where these dyes are, of course, fluorescent dyes, but also will function as Raman tags).

With regard to claim 9, Singer teaches that the barcode binds via the oligonucleotide probe (see column 8, lines 39-43).

With regard to claim 10, Singer teaches that distinguishable barcodes can be generated using multiple copies of the same tag (see column 3, line 59 to column 4, line 6).

With regard to claims 11, 13, 14, 25, 26, Singer teaches a nucleic acid target and detection of the binding to the target (see column 8, lines 39-57).

With regard to claim 15, Singer teaches forming a polymer using monomeric units (see column 8, lines 16-37, where the oligonucleotide synthesizer forms a polymer of nucleotide monomers).

With regard to claims 16-17, Singer teaches monomeric units which comprise different raman tags (see column 3, lines 1-2, where these dyes are, of course, fluorescent dyes, but also will function as Raman tags and see column 8, lines 16-19).

With regard to claims 18, 20, Singer teaches attachment by an amino group, which is a spacer, after the standard commercial oligonucleotide synthesizer step of deprotection (see column 8, lines 32-34).

With regard to claims 19, 24, Singer teaches attachment after polymerization of the monomeric unit (see column 8, lines 32-38).

With regard to claim 21, Singer teaches formation of 31 different subsequences (see column 8, lines 16-32).

With regard to claims 22-23, Singer teaches formation of the oligonucleotide using automated DNA synthesizers, which inherently utilize bead based solid supports (see column 8, lines 32-35).

Singer does not teach the use of branched DNA probes.

Urdea teaches a method of claims 1 and 12 comprising:

(a) obtaining a barcode comprising two or more tags attached to an organic molecule backbone (see figure 11 and column 20, line 35 to column 21, line 49, where the AMP or comb probe is formed by the attachment of branches of nucleotides, and where 14 different tags are attached to the nucleic acid backbone (see column 20, line 38, specifically)),

(b) binding the barcode to a target (see figure 11 and column 21, line 50 to column 22, line 7, where the probes are hybridized to a target),

(c) detecting the barcode bound to the target (see figure 11 and column 22, lines 8-20, where the barcodes are detected).

With regard to claims 2-3, Urdea teaches single stranded nucleic acid probes (see figure 11 and column 20, line 35 to column 21, line 37, where the oligonucleotides were synthesized, and shown as single stranded).

With regard to claim 5, Urdea teaches the use of nucleotide tags which are detected (see figure 11 and columns 20-22).

With regard to claims 6-7, Urdea teaches branched nucleic acids with branches located at predetermined sites along the backbone (see figure 11 and column 20, line 35 to column 21, line 40).

With regard to claim 9, Urdea teaches that the barcode binds via the oligonucleotide probe (see figure 11 and column 21, line 50 to column 22, line 7).

With regard to claim 10, Urdea teaches that distinguishable barcodes can be generated using multiple copies of the same tag (see figure 13, where binding of AMP 1 and AMP2 can be distinguished by LP1 and LP2).

With regard to claims 11, 13, 14, Urdea teaches a nucleic acid target and detection of the binding to the target (see figures 11 and 13 and column 21, line 50 to column 22, line 7).

With regard to claim 12, Urdea teaches a "container" and "probe section" where the tagged LP1 and LP2 probes are hybridized to the AMP probes to create a barcode (see figure 13).

Horn provides a specific motivation to apply the branched DNA (or bDNA) method of Urdea to in situ hybridization methods such as those of Singer (see paragraph 0110-0111).

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to modify the method of Singer to use the sensitive branched DNA probes of Urdea as motivated by Urdea and Horn since Singer recognizes a need for sensitive detection, noting "An imaging technology preferred for sensitive, quantitative detection of fluorochromes is described in Femino (see column 6, lines 32-34). Urdea notes regarding Branched DNA probes that "The invention

increases both the sensitivity and specificity of such assays, by reducing the incidence of signal generation that occurs in the absence of target, and does not involve a substantial increase in either time or cost relative to current assay configurations (see column 2, lines 46-51)." Consequently, Urdea informs the ordinary practitioner that branched DNA probes are desirable for a number of reasons including sensitivity and specificity and reduction in nonspecific signal and these are elements of interest to Singer, who is interested in sensitive quantitative detection in an in situ assay. Horn specifically motivates the use of branched DNA probes in in situ assays such as those employed by Singer, noting "These results demonstrate the usefulness of bDNA in mapping small regions of DNA on a large backbone. Not only was the time to completion greatly shortened using bDNA (1 day or less) but the fluorescence signal using bDNA was considerably higher (see paragraph 0111)." So an ordinary practitioner, interested in sensitive detection using the bar code method of Singer, would have been motivated to further amplify the signal of the bar codes with branched DNA since Urdea indicated that branched DNA improved sensitivity and Horn expressly indicates that branched DNA use in in situ hybridization assays shortened the time to completion while also providing considerably greater fluorescence signal.

Response to Arguments

7. Applicant's arguments with respect to the claims have been considered but are moot in view of the new ground(s) of rejection.

Applicant states that only one claim, claim 6, was incorporated into claim 1. This is not correct. Applicant amended not just one dependent claim, claim 6, into the base

claim, but rather two dependent claims, claims 6 and 8. That combination was not forseeable and could not have been reasonably expected and therefore necessitated this new grounds of rejection. The new grounds is properly necessitated by Applicant's amendment and the action is therefore made final.

Conclusion

8. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman whose telephone number is (571)272-0742. The examiner can normally be reached on 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571)272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jeffrey Fredman
Primary Examiner
Art Unit 1637
10/18/05